ClinicalTrials.govpublic full text
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
metastatic castration sensitive prostate cancer, ipilimumab, degarelix, radical prostatectomy, 13-134, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 841242
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.